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ABSTRACT
Length biased data occurs when a prevalent sampling is used to recruit subjects into
a study that investigates the time from an initial event to a terminal event. Such data
are usually left-truncated and right-censored. While there have been accurate and efficient
methods to estimate the survival function, not much work has been done regarding the
estimation of the residual life time distribution or the summary parameters such as the
median and quantiles of the residual life. This dissertation proposes to make two new
contributions. In the first part of the dissertation, we propose two ways to estimate the
quantiles of the residual life time at fixed time points accounting for the length biased and
censored nature of the data. We provide the asymptotic properties of these estimators
and investigate them through simulation studies. Considering that the variances of these
estimators require density estimation, we suggest an alternate approach taken by Jeong and
others to obtain the confidence interval for the available residual function. We apply these
methods to a breast cancer dataset from the National Surgical Adjuvant Breast and Bowel
Project (NSABP).
In the second part of the dissertation, we propose a method for testing the equality of
quantile residual life times from two different populations under prevalence sampling. This
test can also be inverted to construct confidence intervals for the ratio or difference of two
quantile residual life between two populations. We compare the performance of two methods,
namely, the TPL and Huang and Qin methods via simulation. The results show that the
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proposed tests maintain Type I error. The test based on Huang and Qin survival estimator
is more powerful than that of based on the TPL estimator. We apply our methods to test the
equality of median residual life of breast cancer patients having recurrence and undergoing
two different treatments.
Public health significance of this research is enormous. For a population experiencing
certain disease such as cancer, it is important to estimate the quantiles of the residual life
time at specific time points to assess the impact of a disease and an intervention strategy on
the population. This dissertation will provide accurate and efficient methods for estimating
these quantiles.
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1.0 LENGTH-BIASED DATA AND QUANTILE RESIDUAL LIFE
1.1 LENGTH-BIASED DATA
In epidemiological studies, it is often of interest to study the time between the occurrence
of an initial event and a terminating event. For example, in breast cancer studies it is of
interest to study time from recurrence to death. In mental health studies, it is important to
estimate the time between the onset of depression and the remission to understand the disease
history and its evolution over time. In the ideal scenario, every subject in the population
who experienced the initial event would be followed until the occurrence of the terminating
event and the difference between the times of two events would be computed, which would
result in the distribution of the time to the terminating event from the initiating event. In
reality it is not possible to follow each member of the cohort for the occurrence of these
paired events as it requires unlimited follow-up time. Two practical strategies are usually
taken: an incident cohort study or a prevalent cohort study.
An incident cohort in epidemiology is formed by individuals who experience the initial
events within a specified calendar time interval. These cases are then followed for a further
fixed time period until failure, loss to follow-up or end of the study. For example, a group of
women aged 18 or older may be followed for breast cancer occurrence over a period of five
years and then those who have breast cancer would be followed until death, recurrence, or
termination of the study, A prevalent cohort is a group of individuals who have experienced
the initial event but have not experienced the terminating event at the time of recruitment
into the study. Women diagnosed with breast cancer and alive during the recruitment period
would enter the cohort for follow-up until death, recurrence, or termination of the study.
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In a prevalent cohort study, cross-sectional sampling is used to identify the cases first and
then the cases are followed until failure or censoring. Note that individuals who have already
experienced both the initial and failure event will not be eligible to enter the study. Thus the
prevalent cohort will be biased against individuals with shorter failure event times. Consider
individuals 1 and 5 in Figure 1, both of whom experienced the initial and failure events before
the study recruitment and hence will not be enrolled in the cohort. However, individuals 2
and 3 have not experienced the failure event at the study recruitment and will be enrolled
in the cohort. Similarly, patient 4 would be included as the patient had experienced the
initial event before recruitment. However this patient becomes right censored at the end of
the study. The exclusion of individuals 1 and 5 occurs because of the length of time of the
study, and the bias towards the longer times between the two events is referred to as length
bias.
As mentioned earlier, in prevalence sampling, cases have already experienced their initial
event. These initiating times are assumed to form a stationary poisson process and is referred
to as stationarity. Under stationarity the incidence rate of the disease is approximately
constant over time. The stationarity assumption is not valid when there is an epidemic of
disease before the study starts. But it holds in situations where the disease is stable, that
is, the rate of occurrence of disease (initial event) remains constant over time.
When prevalence sampling is used for recruiting a cohort, left truncation arises. In the
presence of left truncation, we can only observe those individuals whose event time is longer
than a given time. In addition to left truncation, survival data may also be subject to right
censoring. Right censoring occurs when the event occurs after the study ends or a subject
leaves the study (loss-to follow-up). Thus, if the data are right censored, the exact event
time is not known, but it is known to be greater than certain time (e.g. time of last contact).
Failure to account for left-truncation properly results in biased estimation (overestima-
tion) of the survival function. Wolfson et al. (2001) reported that when left-truncation was
not accounted for, the survival rates for patients with dementia from the onset of the disease
was overestimated such that the estimated median survival time was 6.6 years, twice as high
compared to the left-truncation adjusted median of 3.3 years. Thus a proper method of
analysis is essential for making valid inference from length-biased data.
2
X 
X 
X 
X 
1 
Individuals 
2 
3 
4 
5 
- Onset X - Failure - Censored 
Recruitment End of Study 
             Calendar Time 
Figure 1: Prevalent cohort study with follow up.
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In the last several decades, many authors have addressed the issues of left-truncation
and right censoring in survival analysis (Wang et al., 1986[37]; Tsai et al., 1987[29]; and
references therein). Although the concept of a truncation product limit estimator was first
introduced by Lynden-Bell (1971)[22] to account for left truncation, it was only given at-
tention in the 80’s. This estimator is the analogue of the product limit estimator of Kaplan
and Meier (1958)[20] for randomly censored data, and hence is referred to as the trunca-
tion product limit estimator. Wang, Jewel, and Tsai (1986)[37] discussed the asymptotic
properties of this estimator. When the distribution of left truncation time is unspecified, a
conditional analysis is preferred, conditioning on the truncation times (see Turnbull, 1976;
Wang et al., 1986, 1993; Tsai et al., 1987; Lagakos et al., 1988; Wang, 1991, Wang et al.
(1993), Anderson et al. (1993)[1, 21, 29, 30, 35, 36, 36, 37]) as this approach provides a sim-
ple and easy-to-implement expression for the estimator. However, if the onset of a disease
follows a stationary Poisson process such that the incidence rate remains constant over time
(Wang, 1991)[35], i.e., if the stationarity assumption holds, the truncation time will follow
a Uniform distribution and an estimator that incorporates the truncation time distribution
is generally more efficient (Vardi, 1982[31], 1985[32], 1989[32], Gill et al., 1988[15], Vardi
and Zhang (1992)[33], Asgharian et al., 2002[2], and Asgharian and Wolfson, 2005[3]) than
truncation product limit estimator. Vardi (1982[31], 1985[32]) and Gill, Vardi, and Well-
ner (1988)[15] extensively discussed the issues of length-bias and proposed a nonparametric
maximum likelihood estimator (NPMLE) of the underlying non-length-biased survival dis-
tribution. The unconditional estimator, though more efficient, is not easy to implement as
its large-sample properties involve mathematically intractable integral equations (Huang and
Qin, 2011)[17]. Wang (1987)[8] showed that truncation product limit estimator is the non-
parametric maximum likelihood estimator of the full likelihood. Wang (1991)[35] maintained
that the truncation product limit estimator can be derived by maximizing the conditional
likelihood and it has no information loss when the distribution of the truncation time is not
specified. Huang and Qin (2011)[17] provided a new non-parametric estimator incorporating
the distribution of truncation times under stationarity assumption. The new estimator has
a closed-form expression and almost as efficient as the NPMLE.
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1.2 RESIDUAL LIFE TIME
Breast cancer is the most commonly diagnosed cancer and the second leading cause of cancer
deaths in women. With early detection or screening for breast cancer and advances in medical
care and treatments, the mortality rate from breast cancer has significantly reduced in recent
years, yet an astonishing number of women still die from breast cancer every year. According
to American Cancer Society data, 232,340 women will be diagnosed with invasive breast
cancer and 39,620 women will die from breast cancer in 2013. Discovery of new treatments
for both prevention and cure of breast cancer relies on reducing the incidence of breast cancer
and mortality rate respectively in addition to prolonging survival. Thus the role of survival
analysis remains as important as ever in breast cancer research. With the introduction of
new treatment, often the question arises as to which patient is going to respond (e.g. live
longer) to with which treatment. This is because survival time varies substantially across
individuals, even under the same treatment strategies.
From a patient’s perspective, one of the most important questions a woman diagnosed
with breast cancer would like to be answered is about her predicted survival time (time
from diagnosis to death), or even more pragmatically, her remaining life time. A breast
cancer patient deciding to go through a rigorous treatment sequence naturally would like
to know how long her life expectancy would be extended by this treatment. One way to
answer such questions is to provide her an estimated mean survival for patients undergoing
such treatment or an estimate of the probabilities of survival beyond certain times (e.g., 3
years, 5 years, etc.), or to provide her with an estimate of the reduction in risk of death
through the application of the proposed treatment given her physical, demographic, and
other clinical characteristics. These estimates are generally found by analyzing data from
clinical trials, primarily employing statistical tools such as Kaplan-Meier curves (Kaplan and
Meier, 1958[20]), Cox proportional hazards models (Cox, 1972[10]), or accelerated failure
time models (Wei, 1992[38]).
Often a new drug is given in the middle of a follow up period to the patients because of its
potential benefit, and the patient may wish to know her residual life expectancy (how much
the new drug can extend her life expectancy, given that she has survived up to that time).
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Kaplan-Meier plots cannot be used to infer the remaining life years of a patient when the
patients are being followed after the first diagnosis. In recent years, breast cancer patients
who remain recurrence free for several years after initial treatment have been offered new
drugs. It is important for those patients to know the efficacy of the new drug and how it
can prolong their remaining life time. Similarly, it is equally important for the oncologist to
have the ability to explain or predict the remaining lifetime of the patients who are in the
study.
The residual lifetime is the remaining survival time of a person, given that s/he has
already survived up to a certain time. Suppose that a patient has survived up to time t0.
The residual survival time at t0 for this patient is then defined as R
0 = T − t0, where T is
his or her actual survival time. The distribution of the random variable R0 is of interest. In
particular, there are two quantitative features of this distribution that are used to summarize
the distribution of the residual life time R0. They are mean residual life (MRL) function
(Chiang, 1960[9]) and median residual life (MERL) function (Schmittlein and Morrison,
1981[27]). These two functions summarize the residual lifetime distribution in a way which
is easily interpretable to the patients and oncologists alike.
1.2.1 Mean Residual Life Function
The MRL function at a fixed time t0 is defined to be the expected remaining life at that
time t0. Using the notation above, MRL, denoted by µ(t0), is defined as
µ(t0) = E[R
0|T > t0].
For example, if µ(6) = 12 months for treatment and µ(6) = 6 months for placebo, we can
say for patients who are alive at six months, their average remaining life time will be six
months longer on treatment than on placebo.
The MRL function has been extensively studied by many authors over the last several
decades. Yang (1978[40]) considered a natural nonparametric estimator of MRL on a fixed
finite interval and showed that the estimator was uniformly consistent and weakly convergent
to a Gaussian process. Hall and Wellner (1981[16]) extended Yang’s result by constructing
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simultaneous confidence bands for the mean residual life. Oakes and Dasu (1990[25]) pro-
posed a proportional mean residual life model, which is an alternative to the Cox (Cox,
1972[10]) regression model, to study the association between life expectancy and covariates.
Maguluri and Zhang (1994[23]) extended this model with explanatory variables. Chen and
Cheng (2005[7]) used counting process theories to develop semiparametric regression model
with censored data. Chen and Zhao (2004[42]) proposed an empirical likelihood ratio method
for semiparametric inference procedures.
1.2.2 Quantile Residual Life Function
When the data contains censored observations, a very common phenomenon in survival
analysis is that estimated mean residual life function is not reliable. Moreover, even in the
case of complete data, the estimated MRL function can be unfavorable if the underlying
distribution is highly skewed or heavy tailed because of the outliers. As an alternative,
one can consider the median or any other quantile of the residual lifetime. The 100qth
(0 ≤ q ≤ 1) quantile residual life function, denoted by Q(q, t0), is defined as the 100qth
percentile of the distribution of residual life T − t0 among patients in the population who
survived longer than t0. For example, for q = 0.5, Q(0.5, t0) represents the median residual
time at t0 and indicates that among patients who are survivors at time t0, 50% will live
longer than Q(0.5, t0).
While inference about the MRL has been studied by many authors, inference about the
MERL, or more generally the quantile residual lifetime (QRL) are limited in the literature. A
few works studied the estimation and testing of median residual life (MERL) from censored
survival data. For example, Berger et al. (1988[5]) proposed a test Fligner and Rust’s
(1982[13]) approach to compare two median residual lifetimes under censoring. Wang and
Hettmansperger’s (1990[34]) work focused on testing the equality of two quantiles from failure
time distributions under censoring by constructing a confidence interval for the differences
between the two quantiles. Su and Wei (1993[28]) introduced a nonparametric test statistic to
improve upon Wang and Hettmansperger’s test, which requires estimation of the probability
density function of failure times under censoring to evaluate the variance of the median failure
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time. Both methods, however, were intended only for comparing the remaining lifetimes of
patients at the origin of the follow-up period.
Gelfand and Kottas (2003[14]) proposed a Baysian semiparametric approach to the me-
dian residual life regression model. Jeong et al. (2008[18]) proposed a method to estimate
median residual lifetime through Kaplan-Meier survival estimator in a single group. Jung et
al. (2009[19]) proposed a log-linear regression model based on the median residual lifetime
which is an extension of Ying, Jung & Wei (1995[41])’s work.
1.3 SPECIFIC AIMS
The goal of this dissertation is two-fold. First, we propose two consistent and efficient non-
parametric estimators for the quantile residual life function based on length-biased survival
data. We derive the asymptotic properties of the proposed estimators and compare the
proposed estimators in terms of efficiency and coverage probabilities. Furthermore, we derive
test statistics to test the equality of quantiles of residual life from two populations with
length-biased samples. We also provide the asymptotic properties of the proposed test
statistics, and evaluate the proposed test based on Type I error and Power.
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2.0 NONPARAMETRIC ESTIMATION OF QUANTILE RESIDUAL LIFE
FOR LENGTH-BIASED SURVIVAL DATA
In this chapter we propose non-parametric estimators for the quantile residual life function
based on length-biased survival data. Specifically, we propose two estimators of quantile
residual life function based on survival functions estimated using Truncation Product limit
method and Huang and Qin (2011) method, respectively, and show that the latter is more
efficient than the former. We will build upon the techniques presented in Jeong et al.
(2008[18]) to construct confidence intervals for the quantiles of length-biased right-censored
survival data.
2.1 DATA SET-UP AND NOTATION
Let T 01 , T
0
2 , T
0
3 , . . . be i.i.d. positive random variables representing the time from disease
incidence to failure event. Denote by S(t) and f(t) the survival and probability density
function of T 0 (note that we drop the subscript i to represent a generic copy of the i.i.d
variables) respectively. Let W 0 denote the calender time of disease incidence and ξ be
the potential recruitment time. A prevalent population would include individuals with the
disease who have not experienced the failure event at the sampling time, that is, the prevalent
population would consist of failure times for which T 0 ≥ ξ −W 0 > 0. We will use W and
T to indicate the ‘observed’ W 0 and T 0 respectively in the prevalent population.
For stable disease, we assume two conditions : (i) the probability distribution of survival
time T 0 is independent of W 0, and, (ii) the occurrence rate of disease remains constant over
calender time, that is, W 0 has a constant density function.
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Let A = ξ −W be the truncation time from disease incidence to sampling time and let
V = T − A be the residual survival time from sampling time. Let fT (t), fA(t) and fV (t) be
the marginal density functions and ST (t), SA(t) and SV (t) be the survival functions of the
corresponding the random variables T,A and V .
When conditions (i) and (ii) are satisfied, (A, T ) has the joint density function:
fA,T (a, t) = cf(t)I(t > a > 0), (2.1)
where c is a constant. This means that,
∫∞
0
∫ t
0
cf(t)dadt = 1
⇔ c ∫∞
0
f(t)tdt = 1
⇔ c = 1∫∞
0 tf(t)dt
= 1
µ
.
where µ = E(T 0). Therefore, the joint distribution of A and T is given by,
fA,T (a, t) =
1
µ
f(t)I(t > a > 0). (2.2)
The marginal distribution of length-biased survival time T is then obtained as
fT (t) =
∫ t
0
1
µ
f(t)da =
1
µ
tf(t)I(t > 0) (2.3)
The marginal distribution of truncation time A is then
fA(a) =
∫ ∞
a
1
µ
f(t)dt =
1
µ
S(a)I(a > 0). (2.4)
The conditional distribution of T given A is
f(T |A=a)(t) =
fA,T (t, a)
fA (a)
=
1
µ
f(t)
1
µ
S(a)
=
f(t)
S(a)
, (2.5)
and the corresponding survival function is
S(T |A=a)(t) = P (T > t|A = a) = 1
S(a)
∫ ∞
t
f(t) dt =
S(t)
S(a)
. (2.6)
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The marginal distribution of V = T − A can also be derived as
fV (v) =
1
µ
S(v)I(v > 0). (2.7)
The second assumption of the occurrence rate of disease being constant over calender
time is often referred to as stationarity. The consequence of this assumption is that the
truncation time A given T is uniformly distributed. This follows from that fact that if a
person lives up to time T , then because the initial event occurs at a constant rate, it could
occur at any time before T with equal probability. That the marginal distribution of V
and A are identical provides us a way to test the stationarity assumption. Asgharian et
al. (2006[4]) suggested checking this in the data graphically by comparing the estimated
distributions (Kaplan-Meier curves) of V and A.
Our interest lies in statistical inference for the distribution of residual lifetime at a specific
timepoint s of the population represented by the survival time T 0. Specifically our objective
is to estimate the 100qth quantile residual lifetime function Q(q, s) at time s, defined by,
Pr(T 0 − s > Q(q, s)|T 0 > s) = 1− q, (2.8)
where 0 ≤ q ≤ 1. Or, equivalently, Q(q, s) is the solution to the equation
S(s+Q)
S(s)
= 1− q (2.9)
The 100qth quantile residual lifetime for the prevalent population Q∗(q, s) is defined as
P (T − s > Q∗(q, s)|T > s) = 1− q,
⇔ ST (s+Q
∗)
ST (s)
= 1− q,
where
ST (s) =
∫ ∞
s
tf(t)
µ
I(t > 0)dt
=
1
µ
∫ ∞
s
tf(t)dt.
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Since the survival functions S(.) and ST (.) are not same, Q
∗ is not necessarily the same
as Q, and hence the estimator for Q∗ based on the estimated survival function of T might
not be a good estimator of Q.
Suppose that individual i has censoring time C∗i = Ai + Ci, where Ci is the residual
censoring time, the time from recruitment until the individual is censored and Ti = Ai + Vi,
is the overall survival time, such that Vi is the time from recruitment to failure event. We can
observe only min(C∗i , Ti), We also assume that Ci is independent of (ξi,Wi, Ti). However, the
total survival time Ti and the total censoring time C
∗
i have Ai in common and are dependent.
Thus the total survival time Ti is subject to informative censoring (Vardi, 1989). Informative
censoring occurs when the censoring time, C∗i gives more information on the survival time
Ti, in addition to the knowledge that Ti > C
∗
i .
Under right censoring of the survival time, we observe (Wi, Ai, V˜i,∆i), where V˜i =
min(Vi, Ci) and ∆i = I(Vi ≤ Ci), for i = 1, ......, n where n is the number of individuals
in the sample. Define Yi = Ai + V˜i = min(Ti, C
∗
i ).
2.2 ESTIMATION OF THE QUANTILE RESIDUAL FUNCTION
As defined in the previous section (Equation (2.8)), the 100qth quantile residual lifetime
function Q(q, s) at time s is given by
P (T 0 − s ≥ Q(q, s)|T 0 > s) = 1− q.
The left hand side of the above equation can be expressed as
P (T 0 − s ≥ Q(q, s)|T 0 > s)
=
P (T 0 − s ≥ Q(q, s), T 0 > s)
P (T 0 > s)
=
P (T 0 ≥ s+Q(q, s)), P (T 0 > s)
P (T 0 > s)
=
P (T 0 ≥ s+Q(q, s))
P (T 0 > s)
=
S(s+Q(q, s))
S(s)
. (2.10)
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Thus the 100qth quantile of the residual lifetime distribution at a fixed time t0 can be
calculated as a solution to the equation
u(Q) = S(t0 +Q)− (1− q)S(t0) = 0. (2.11)
Note that for simplicity we have used Q for Q(q, t0). To estimate Q, one would replace the
survival function S(.) by its sample estimate, and solve the same equation for Q. In other
words, Q would be estimated by solving the equation uˆ(Q) = 0 where
uˆ(Q) = Sˆ(t0 +Q)− (1− q)Sˆ(t0), (2.12)
where Sˆ(t) is a uniformly consistent estimator of the survival function in the prevalent
population [35].
Different choices of Sˆ(.) might lead to different estimates of Q. Here we will consider two
estimates of S(.). One is the traditionally used truncation product limit (TPL) estimator
by Tsai et, al. (1987[29]), and the other is a recently proposed estimator by Huang and Qin
(2011[17]).
The TPL estimator of S(.) based on the length-biased data is
Sˆ(t) =
∏
u∈[0,t]
{1− dΛˆ(u)} (2.13)
where Λˆ is the estimated cumulative hazard function
Λˆ(t) =
∫ t
0
dN¯(u)
R¯(u)
(2.14)
with N¯(u) = n−1
∑n
j=1 ∆jI(Yj ≤ u) and R¯(u) = n−1
∑n
j=1 I(Yj ≥ u ≥ Aj)
The Truncation product-limit estimator ignores the information in the marginal distri-
bution of Aj, which can be very inefficient in the situation where the data comes from a
length-biased sample. Huang and Qin (2011) argued that the truncation time A has the
same marginal distribution as the residual survival time V under length-biased sampling.
They estimate SA and Λ by combining the information from both A and V which leads to
a more efficient estimator than TPL estimator.
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The survival estimator proposed by Huang and Qin (2011) is given by
Sˆ∗(t) =
∏
u∈[0,t]
{1− dΛ˜(u)} (2.15)
with the corresponding estimated cumulative hazard function defined as
Λ˜(t) =
∫ t
0
dN¯(u)
R˜(u)
, (2.16)
where
R˜(u) = n−1
n∑
i=1
I(Yi ≥ u)− S˜A(u),
S˜A(u) =
∏
t∈[0,u]
{
1− dB˜(t)
K˜(t)
}
,
B˜(t) = n−1
n∑
i=1
{I(Ai ≤ t) + ∆iI(V˜i ≤ t)},
and
K˜(t) = n−1
n∑
i=1
{I(Ai ≥ t) + I(V˜i ≥ t)}.
Our first proposed estimator uses Sˆ(t) for S(t) in Equation (2.12) and solves the equation
for Q to obtain an estimator Qˆ of Q. This means that
Sˆ(t0 + Qˆ) = (1− q)Sˆ(t0)
⇒ Qˆ = Sˆ−1((1− q)Sˆ(t0))− t0,
where Sˆ−1(.) is the inverse of the estimated survival function defined as
Sˆ−1(p) = inf{t : Sˆ(t) < p} (2.17)
for 0 < p < 1. Note that, this implies that Qˆ exists only if Sˆ−1(p) exists at p =
(1− q)Sˆ(t0); or equivalently, there exists a t for which Sˆ(t) < (1− q)Sˆ(t0).
In a similar fashion, we define the estimator Qˆ∗ of Q. Specifically, Qˆ∗ is the solution of
the equation uˆ∗(Q) = 0 for Q where
uˆ∗(Q) = Sˆ∗(t0 +Q)− (1− q)Sˆ∗(t0).
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In other words,
Qˆ∗ = [Sˆ∗((1− q)Sˆ∗(t0))]−1 − t0,
and Qˆ∗ exists only when there is at least one t for which Sˆ∗(t) < (1− q)Sˆ∗(t0).
2.3 ASYMPTOTIC PROPERTIES AND INFERENCE
It has been shown that Sˆ(t) is uniformly consistent and asymptotically normal (Wang, 1991)
for 0 ≤ t ≤ τ , where τ is such that a positive proportion in the population is alive beyond
τ . Moreover, this estimator is asymptotically linear such that
√
n
{
Sˆ(t)− S(t)
}
= n−1/2
n∑
i=1
φi(t) + op(1), (2.18)
where
φi(t) =
[∫ t
0
R(u)−2I(Yi ≥ u ≥ Ai)dF u(u)− ∆iI(Yi ≤ t)
R(Yi)
]
S(t).
R(u) = pr(Y ≤ u ≤ A) and F u(t) = pr(∆ = 1, Y ≤ t) is the subdistribution function of
complete observations. The variables φi, i = 1, 2...., n are i.i.d. with E(φi) = 0 and variance
covariance function Σ(t1, t2) = E{φi(t1)φi(t2)}, 0 ≤ t1, t2 ≤ τ , and are referred to as the
influence function of Sˆ(t).
Huang and Qin (2011) established that Sˆ∗(t) is uniformly consistent and asymptotically
normal with
√
n
{
Sˆ∗(t)− S(t)
}
= n−1/2
n∑
i=1
φ∗i (t) + op(1), (2.19)
where
φ∗i (t) = φi(t) +
∫ t
0
R(u)−2{I(Ai > u)− SA(u)− SA(u)φi(u)}dF u(u),
i = 1, 2....., n, are i.i.d random variables with mean zero and the covariance function
Σ∗(t1, t2) = E [φ∗i (t1)φ
∗
i (t2)] .
Now, the estimator Qˆ is a solution to the estimating equation
uˆ(Q) = 0, (2.20)
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where uˆ(.) is defined in (2.12), with Sˆ(t) calculated using Equation (2.13).
That is,
uˆ(Q) = Sˆ(t0 +Q)− (1− q)Sˆ(t0). (2.21)
Since Sˆ(t) is uniformly consistent over t ∈ [0, τ ], uˆ(Q) uniformly converges to
u(Q) = S(t0 +Q)− (1− q)S(t0) (2.22)
for t ∈ [0, τ ]. Since u(Q0) = 0 at the true value Q0 = Q(t0, q), the estimated 100qth quartile
residual life of T 0 at time t0, Qˆ is a consistent estimator of Q0.
As with all quantile estimators, finding the asymptotic distribution of Qˆ through the
expansion of uˆ(Q) involves the estimation of the density function of T , which appears in
the denominator of the variance expression. Since density estimators are highly variable and
can often take values that are close to zero, the estimated variance of Qˆ calculated in this
manner is highly unstable. To overcome this, Jeong et al. (2008) suggested directly obtaining
the confidence interval for Q by inverting a standardized statistic based on uˆ(Q). This is
a procedure similar to that suggested in Brookmeyer and Crowley (1982[6]) for obtaining
confidence interval for quantiles. Thus, one would need to find the asymptotic distribution
of uˆ(Q0). We note that
√
nuˆ(Q0) =
√
n{uˆ(Q0)− u(Q0)}
=
√
n{Sˆ(t0 +Q0)− (1− q)Sˆ(t0)− S(t0 +Q0) + (1− q)S(t0)}
=
√
n{Sˆ(t0 +Q0)− S(t0 +Q0)} −
√
n(1− q){Sˆ(t0)− S(t0)}, (2.23)
Using (2.18),
√
nuˆ(Q0) = n
− 1
2
∑
φi(t0 +Q0)− n− 12 (1− q)
∑
φi(t0) + op(1)
= n−
1
2
∑
φui + op(1), (2.24)
where φui = φi(t0 +Q0)− (1− q)φi(t0). Therefore,
√
nuˆ(Q0) is asymptotically distributed as
normal with mean zero and variance
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V0(Q0) = var(φ
u
i )
= var[φi(t0 +Q0)− (1− q)φi(t0)]
= Σ(t0 +Q0, t0 +Q0) + (1− q)2Σ(t0, t0)− 2(1− q)Σ(t0 +Q0, t0), (2.25)
where Σ(t1, t2) = E{φi(t1)φi(t2)}.
For known Q0 this variance can be estimated by
Vˆ0(Q0) = Σˆ(t0 +Q0, t0 +Q0) + (1− q)2Σˆ(t0, t0)− 2(1− q)Σˆ(t0 +Q0, t0),
where
Σˆ(t1, t2) =
1
n
Σni=1φˆi(t1)φˆi(t2)
with
φˆi(t) = Sˆ(t)
[∫ t
0
I(Yi ≥ u ≥ Ai)dN¯(u)
Rˆ2(u)
− ∆iI(Yi ≤ t)
Rˆ(Yi)
]
.
A 100(1− α)% confidence interval for Q can then be constructed by inverting the Wald
statistic based on the asymptotic distribution of
√
nuˆ(Q0). More explicitly, a 100(1 − α)%
confidence interval for Q is given by
{Q : [Vˆ0(Q)]−1n[uˆ(Q)]2 < χ21,1−α}, (2.26)
where χ21,1−α is the 100(1− α)th percentile of a χ2 distribution with 1 degree of freedom.
A similar argument can be used to construct a confidence intervals for Q using the other
estimator Qˆ∗. Explicitly, a 100(1−α)% confidence interval for Q using this method is given
by,
{Q : [Vˆ0∗(Q)]
−1
n[uˆ∗(Q)]2 < χ21,1−α},
where
uˆ∗(Q) = Sˆ∗(t0 +Q)− (1− q)Sˆ∗(t0),
Vˆ0
∗
(Q) = Σˆ∗(t0 +Q, t0 +Q) + (1− q)2Σˆ∗(t0, t0)− 2(1− q)Σˆ∗(t0 +Q, t0),
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Σˆ∗(t1, t2) =
1
n
n∑
i=1
φˆi
∗
(t1)φˆi
∗
(t2),
with
φˆi
∗
(t) = Sˆ∗(t)
[∫ t
0
I(Yi ≥ u ≥ Ai)dN¯(u)
R˜2(u)
− ∆iI(Yi ≤ t)
R˜(Yi)
+
∫ t
0
{
I(Ai > u
R˜2(u)
− S˜A(u)− S˜A(u)ψ˜i(u)
}
dN¯(u)
]
,
where
ψ˜i(u) =
∫ t
0
{I(Ai ≥ u) + I(V˜i ≥ u)}dB˜(u)
K˜2(u)
− I(Ai ≤ t)
K˜(Ai)
− ∆iI(V˜i ≤ t)
K˜(V˜i)
.
2.4 SIMULATION STUDY
We conducted a simulation study to evaluate the finite-sample performance of the two es-
timators of quantile residual life functions discussed in the previous sections, namely, Qˆ∗
calculated based on Huang Qin method, and Qˆ based on the truncation product-limit es-
timator. We generated 1000 Monte-Carlo samples of sizes n (200 or 400) from the target
population. The population parameters were chosen to be similar to simulation conducted
by Huang and Qin (2011). More explicitly, we first set the sampling time (recruiting time) ξ
to be 100. The time of disease onset W 0 was generated from a uniform distribution over the
interval [0, 100]. The survival time T 0 was independently generated from a Weibull distri-
bution with the survival function S(t) = exp(−t2/4). To form a prevalent cohort of sample
size n, the pair (W 0, T 0) were generated repeatedly until there were n pairs of observations
satisfying the sampling constraint W 0 + T 0 ≥ ξ. The residual censoring time C from enroll-
ment to loss to follow-up was generated from a uniform distribution with a support (1, 2) or
(0, 2) resulting respectively in 30% and 51% censoring rates.
The true 100qth quantile residual life function at time t0 for the Weibull distribution
above is given by
exp{−(t0 +Q(q, t0))2/4} − (1− q)× exp(−t20/4) = 0,
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which is equivalent to the positive root of the quadratic equation
Q2(q, t0) + 2Q(q, t0)t0 + 4 ln(1− q) = 0.
Thus the true 100qth quantile residual life function at time t0 is
Q(q, t0) =
√
t20 − 4 ln(1− q)− t0. (2.27)
Figure 2 shows the true QRL function for various values of q, specifically, the 25th, 50th,
and 75th percentile of residual life function.
We show the numerical results for estimating these residual life functions at fixed time
points 0.0, 0.5, and 1.0. We present the bias, average length and coverage probability of 95%
confidence intervals for the two estimates, Qˆ and Qˆ∗.
Table 1 the summarizes mean of 75th quantile residual life function, bias, the average
length of 95% confidence interval, and the coverage probability of 95% confidence interval
for both estimators at different time points (0.0, 0.5, 1.0) for two sample sizes n = (200, 400)
based on 1000 Monte-Carlo samples. The true 75th quantile residual life functions at the
selected time points (0.0, 0.5, 1.0) are respectively (2.35, 1.91, 1.56). When censoring was
moderate (30%), both estimators were approximately unbiased with bias being relatively
smaller for the Qˆ∗ for the larger sample size of 400; the bias ranged from −0.0032 to 0.0013
for Qˆ and −0.0006 to 0.0064 for the Qˆ∗. In general, the coverage probabilities of the 95%
confidence intervals met the nominal level, specifically for the larger sample size of 400;
(91.6% − 94.5%) for Qˆ and (93.0% − 95.1%) for Qˆ∗. Average length of these confidence
intervals was generally wider for Qˆ. For example, at n = 200 the average length of the 95%
confidence intervals was 0.47 for Qˆ versus 0.41 for Qˆ∗, showing a 12.8% reduction. This
reduction in the length of the confidence interval is equivalent to an increase in efficiency
for Qˆ∗. When sample size was increased from 200 to 400, the confidence intervals became
narrower as shown by the decrease in the average length of the intervals for both methods.
However Qˆ∗ still resulted in narrower confidence intervals with a 9.4% to 15.4% reduction in
average length as compared to Qˆ. This is equivalent to an efficiency gain of 21.8% to 39.7%
for Qˆ∗ over Qˆ.
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Figure 2: Graphical representation of the true quantile residual life function for various
values of q.
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Table 1: Simulation results for estimating the 75th quantile residual life function depicted
in Figure 2. EST = Monte Carlo mean of the estimator, BIAS = absolute bias of the esti-
mator, AL = Monte Carlo average of the length of 95% confidence interval, CP = Coverage
probability of 95% confidence interval.
% cen t0 n Q(0.75, t0) Qˆ BIAS AL CP Qˆ
∗ BIAS AL CP
0.0 200 2.35 2.35 -0.0003 0.47 91.6 2.36 0.0059 0.41 93.7
30% 0.5 1.91 1.91 0.0013 0.45 91.7 1.91 0.0064 0.40 93.0
1.0 1.56 1.56 0.0013 0.45 92.0 1.56 0.0040 0.40 93.6
0.0 400 2.35 2.35 -0.0032 0.33 92.5 2.36 0.0004 0.29 93.6
0.5 1.91 1.91 -0.0016 0.32 94.5 1.91 0.0006 0.28 93.7
1.0 1.56 1.56 -0.0027 0.32 94.1 1.56 -0.0006 0.29 95.1
0.0 200 2.35 2.36 0.0005 0.56 93.1 2.36 0.0039 0.48 93.1
51% 0.5 1.91 1.91 0.0027 0.55 92.5 1.91 0.0066 0.47 93.1
1.0 1.56 1.56 0.0062 0.55 92.9 1.57 0.0086 0.49 95.1
0.0 400 2.35 2.35 -0.0038 0.40 92.4 2.35 -0.0001 0.34 93.1
0.5 1.91 1.91 -0.0018 0.39 92.2 1.91 0.0009 0.33 94.0
1.0 1.56 1.56 -0.0022 0.39 93.3 1.56 -0.0008 0.35 93.8
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Table 2: Simulation results for estimating the 50th quantile residual life function depicted
in Figure 2. EST = Monte Carlo mean of the estimator, BIAS = absolute bias of the esti-
mator, AL = Monte Carlo average of the length of 95% confidence interval, CP = Coverage
probability of 95% confidence interval.
% Cen t0 n Q(0.50, t0) Qˆ BIAS AL CP Qˆ
∗ BIAS AL CP
0.0 200 1.67 1.66 -0.0004 0.45 92.3 1.67 0.0034 0.40 93.7
30% 0.5 1.24 1.24 0.0024 0.39 93.5 1.24 0.0059 0.36 94.3
1.0 0.94 0.94 0.0016 0.35 92.2 0.94 0.0026 0.33 93.9
0.0 400 1.67 1.66 -0.0040 0.31 92.4 1.67 0.0008 0.28 93.2
0.5 1.24 1.24 0.0004 0.28 93.0 1.24 0.0024 0.25 92.8
1.0 0.94 0.94 -0.0029 0.25 91.9 0.94 -0.0009 0.23 92.4
0.0 200 1.67 1.67 0.0023 0.51 92.6 1.67 0.0049 0.46 93.1
51% 0.5 1.24 1.24 0.0042 0.47 93.9 1.25 0.0065 0.42 93.8
1.0 0.94 0.95 0.0029 0.43 92.4 0.95 0.0053 0.39 93.9
0.0 400 1.67 1.66 -0.0037 0.36 91.9 1.67 0.0010 0.32 93.8
0.5 1.24 1.24 0.00003 0.33 92.0 1.24 0.0009 0.29 92.8
1.0 0.94 0.94 -0.0011 0.30 91.9 0.94 0.0007 0.27 92.3
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Table 3: Simulation results for estimating the 25th quantile residual life function depicted
in Figure 2. EST = Monte Carlo mean of the estimator, BIAS = absolute bias of the esti-
mator, AL = Monte Carlo average of the length of 95% confidence interval, CP = Coverage
probability of 95% confidence interval.
%Cen t0 n Q(0.25, t0) Qˆ BIAS AL CP Qˆ
∗ BIAS AL CP
0.0 200 1.07 1.07 -0.0013 0.49 90.8 1.08 0.0042 0.47 93.1
30% 0.5 0.68 0.69 0.0049 0.37 91.4 0.69 0.0074 0.36 91.6
1.0 0.47 0.47 0.0024 0.29 93.8 0.47 0.0041 0.27 93.9
0.0 400 1.07 1.07 -0.0006 0.35 92.1 1.08 0.0026 0.34 92.8
0.5 0.68 0.69 0.0034 0.27 91.4 0.69 0.0048 0.25 91.2
1.0 0.47 0.47 -0.0011 0.20 93.4 0.47 -0.0001 0.19 93.6
0.0 200 1.07 1.07 0.0016 0.53 92.2 1.08 0.0053 0.50 93.2
51% 0.5 0.68 0.69 0.0063 0.42 91.4 0.69 0.0068 0.40 91.9
1.0 0.47 0.47 0.0039 0.34 93.6 0.47 0.0051 0.33 93.8
0.0 400 1.07 1.07 -0.0005 0.38 93.5 1.08 0.0028 0.36 93.2
0.5 0.68 0.69 0.0035 0.30 92.2 0.69 0.0050 0.28 92.4
1.0 0.47 0.47 0.0007 0.24 93.6 0.47 0.0022 0.23 93.4
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When the censoring rate was increased to 51%, the biases were increased for both esti-
mators but they remained small. With the increased censoring, Qˆ∗ almost always provided
better coverage for the 95% confidence interval for both smaller (200) and larger (400) sample
sizes, compared to Qˆ.
Table 2 shows the results for estimating the median residual lifetimes at times (0.0, 0.5, 1.0).
The results are similar to those described for 75th quantile estimators. Specifically both Qˆ
and Qˆ∗ are approximately unbiased and maintain the nominal coverage probability at mod-
erate to extreme levels of censoring and sample sizes. However, Qˆ∗ is more efficient (has
narrower confidence intervals). Also, the coverage probabilities are almost uniformly better
for Qˆ∗ as compared to Qˆ. The same trend followed for the 25th percentile residual estimator
[Table 3].
In summary, the two proposed estimators of quantile residual lifetime provide reasonable
estimates with Qˆ∗ being more efficient than Qˆ, in general.
2.5 ANALYSIS OF NSABP B-20 DATA
In this section we illustrate our method using the data from the National Surgical Adjuvant
Breast and Bowel Project (NSABP) protocol B-20 clinical trial. Protocol B-20 was designed
to determine whether addition of chemotherapy to tamoxifen would improve the beneficial
effect of tamoxifen in the treatment of estrogen receptor (ER) positive patients with axillary
lymph node-negative breast cancer. Women at participating NSABP clinical centers in the
USA and Canada who had primary breast cancer, histologically node-negative and ER pos-
itive breast cancer were eligible for this trial. Patients fulfilling eligibility criteria underwent
surgery (total mastectomy and lymph node dissection or lumpectomy and lymph node dissec-
tion followed by breast irradiation). Following surgery, patients providing written consent to
participate in the trial were randomized to one of the three treatment groups: tamoxifen(T)
alone (TAM), T plus sequential methotrexate (M) and fluorouracil (F) (MFT), T plus cy-
clophosphamide (C), M, and F (CMFT) stratified by age, tumor size, and tumor ER level.
Between Oct 17, 1988, and March 5, 1993, a total of 2363 women were enrolled in this study
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(788 randomly assigned to TAM, 786 to MFT, and 789 to CMFT). Earlier findings from this
clinical trial (Fisher et al., 1997[11]) analyzing 5-year follow-up data showed that addition of
chemotherapy to tamoxifen significantly improved the disease-free survival (DFS) rate by at
least 4%, MFT vs. TAM (90% vs. 85%, p = .01) and CMFT vs. TAM (89% vs. 85%, p =
.001). Chemotherapy plus Tamoxifen groups (MFT and CMFT) perform significantly better
in DFS than tamoxifen alone(Fisher et al., 1997). Similar results were observed for distant
disease-free survival and overall survival. In a follow-up publication, Fisher et al., (2004[12])
showed that CMFT-treated women had significantly better recurrence-free survival (89% vs.
79%, p<0.0001) and better overall survival (87% vs. 83%, p = 0.063) than women treated
with tamoxifen alone over 12 years of follow-up.
This difference might prompt one to characterize the pattern of survival among patients
with recurrence. Recurrence of cancer is not uncommon among breast cancer patients treated
with tamoxifen. In the B-20 trial, over 18 years of follow-up, it has been observed that 17%
of the women experienced recurrence before death. Thus it might be of interest to estimate
the residual survival following a recurrence in histologically node-negative and ER-positive
breast cancer patients who are being treated with tamoxifen with or without chemotherapy.
Thus, our initial event will be recurrence, and the primary endpoint will be death.
A total of 788 women were randomly assigned to receive Tamoxifen. Out of these 788
women, 170 women experienced recurrence. To construct a length-biased sample of patients,
we identified the date of recurrence for the first patient who experienced recurrence and set
the recruitment time to be at 5 years following this first recurrence date. By the recruitment
date, 120 patients had died or been lost-to-follow-up and hence would not be eligible to be in
the sample. (Alternatively, a window can be considered for recruitment, but for simplicity,
we will assume that all patients are recruited at once.) Thus, our length-biased sample
consists of 50 patients who had recurrence prior to September 17, 1994 and were still being
followed at the same date. We will estimate the quantile residual lifetimes of these patients.
Table 4 presents the estimated 25th percentile and median for the residual life times for
patients who experienced recurrence following treatment with tamoxifen based on the NS-
ABP B-20 data at times 0, 0.5 and 1 years after recurrence. We also provide 95% confidence
intervals for both estimates. For this specific dataset the TPL estimates of quantile residuals
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Table 4: Estimated quantile residual lifetimes and 95% confidence interval in the Tamoxifen
arm of the NSABP B-20 data
q t0 Qˆ
(q, t0) 95% CL Qˆ
∗(q, t0) 95% CL
0.0 1.48 ( 1.27, 3.29 ) 1.37 ( 1.26, 2.59 )
.25 0.5 0.98 ( 0.77, 2.79 ) 0.87 ( 0.76, 2.09 )
1.0 0.48 ( 0.27, 2.29 ) 0.37 ( 0.26, 1.59 )
0.0 3.11 ( 1.49, 10.32) 2.36 ( 1.42, 4.34 )
.50 0.5 2.61 ( 0.99, 9.82 ) 1.86 ( 0.92, 3.84 )
1.0 2.11 ( 0.49, 9.32 ) 1.36 ( 0.42, 3.34 )
(Qˆ) were generally larger than Qˆ∗, which employs the distribution of truncation time. For
example, at the time of recurrence, the estimated median residual lifetime estimated by Qˆ∗
is approximately 2.4 years compared to 3.1 years for Qˆ. At 1 year, the median residual
life time (95% CI) for patients with recurrence after tamoxifen treatment is approximately
1.36(0.42, 3.34) years by Qˆ∗ compared to 2.11(0.49, 9.32) years by Qˆ. Similar results follow
for the 25th percentile.
In Figure 3, we present the estimated median residual lifetimes and their pointwise
confidence intervals for the NSABP B-20 patients experiencing recurrence. Consistent with
the results shown in Table 4, the Qˆ∗ estimates are uniformly smaller than the Qˆ estimates.
Median residual lifetime first decreases until between 1 to 1.2 years after recurrence and
then increases. This could potentially be the effect of post-recurrence treatment which the
patients may have received outside the protocol. The confidence intervals are wider for Qˆ
estimators compared to Qˆ∗ estimators, as expected from the simulation results.
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Figure 3: Estimated median residual lifetimes and 95% confidence intervals for time to death
from recurrence for the NSABP B-20 data.
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2.6 DISCUSSION
Length-biased data are common in epidemiological prevalent cohort studies where the time
between an initial event and a terminal event is of interest. In this chapter, we have proposed
two different approaches to estimate the length-bias corrected quantile residual life (QRL)
function for a prevalence sample. The first estimator is based on the truncation product
limit estimator (Wang et al., 1986) and the second is based on the Huang and Qin (2011)
survival estimator. We have developed the asymptotic properties procedures for the two
estimators and demonstrated how the confidence interval for QRL can be constructed by
inverting a proposed test statistic.
Simulation results showed that both methods empirically lead to consistent QRL esti-
mates, but the QRL estimator based on Huang and Qin method is more efficient than TPL
estimator as shown by the narrower confidence intervals for the former compared to the lat-
ter. Both estimators maintain nominal coverage levels, though the coverage is often smaller
than the nominal 95%.
We have illustrated our methods with a breast cancer dataset from one of the NSABP
studies, estimating the quantiles of residual lifetime for breast cancer patients experiencing
a recurrence.
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3.0 TEST OF EQUALITY OF QUANTILE RESIDUAL LIFES FOR
LENGTH-BIASED SURVIVAL DATA
3.1 INTRODUCTION
In epidemiological studies, it is often of interest to compare two populations with respect to
the time between the occurrence of an initial event and a terminating event. In breast cancer
studies, it may be of interest to compare time from recurrence to death among patients
who are treated with tamoxifen to that for patients who were additionally treated with
other chemotherapy agents. As discussed in Chapter 1, such times are length-biased due to
prevalence sampling and hence regular Kaplan-Meier estimators are not suitable (Klein and
Moeschberger, 2003[24]). Consequently, the comparison of the quantile residual life based on
such estimators will also be biased. In this part of the dissertation, we propose methods for
unbiased testing of the equality of quantile residual lifes for two different populations under
prevalence sampling. As a byproduct we will be able to construct confidence intervals for
the ratio or difference of two quantile residual lifes between two populations by inverting the
corresponding tests.
Testing the equality of medians from censored survival data has been of interest to re-
searchers for a long time. The famous Brookmeyer and Crowley paper (Brookmeyer and
Crowley, 1982; Wang and Hettmansperger, 1990) discusses a test statistic that requires esti-
mation of the density function, which is often not straightforward in the presence of censoring.
This limitation was overcome by Su and Wei (1993) , who proposed a nonparametric test
statistic for comparing two median failure times based on the minimum dispersion statistic
(Basawa and Koul, 1988). Jeong et al. (2008) extended this to the case of equality testing
of two median residual life functions for censored survival data. However, these methods are
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not applicable when data are collected through prevalence sampling. We propose two test
statistics based on the two estimation approaches discussed in Chapter 2. We compare the
performance of the two statistics based on the Type I error and power.
3.2 THE TWO-SAMPLE TEST FOR QUANTILE RESIDUAL LIFE
3.2.1 Notation
Suppose T 0j , j = 1, 2, denotes the variables representing the time between the two events
(initial and terminating) in the jth parent population. Suppose Qj ≡ Qj(q, t0) denote the
100qth (0 ≤ q ≤ 1) quantile residual life function for the jth population at time t0. In other
words, Qj is the 100qth percentile of the distribution of residual life T − t0 among patients
in the jth population who survived longer than t0. Our goal is to test the null hypothesis
H0 : Q1 = Q2
for fixed t0 and to construct confidence intervals for functions of Q1 and Q2, g(Q1, Q2), such
as the difference of the two QRLs
g(Q1, Q2) = Q1 −Q2,
or the ratio of two QRLs
g(Q1, Q2) =
Q1
Q2
.
The data set-up is similar to that in Chapter 2, except that all the variables will be
indexed by j to indicate the respective population the data are being sampled from. In
brief, for the jth(j = 1, 2) population,we assume:
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Symbol Description
T 0j = Time between initial event and terminating event in population j
Sj(t) = Survival function of T
0
j at time t
Qj = Qj(q, t0) QRL of population j at time t0
Wj = Calender time of initial event
Aj = Time between initial event and recruitment
Vj = Time between recruitment and terminating event
Cj = Time from recruitment until the individual is censored
nj = Sample size for the jth group
Thus the observed data in this two-sample case consist of the following random vectors,
(Wji, Aji, V˜ji,∆ji) where V˜ji = min(Vji, Cji) and ∆ji = I(Vji ≤ Cji), j = 1, 2; i = 1, ......, nj .
We make the following assumptions:
1. The samples are independent. That is, (W1i, A1i, V˜1i,∆1i, i = 1, ......, n1) is independent
of (W2i, A2i, V˜2i,∆2i, i = 1, ......, n2).
2. The Residual censoring times Cji’s are independent of (Wji, Tji) for j = 1, 2.
As in Chapter 2, define Yji = Aji + V˜ji = min(Tji, C
∗
ji) to be the observed time to the
terminating event or censoring, whichever occurs first, from the initial event.
3.2.2 Estimators for Qj
Following the derivations in Chapter 2, Qj, j = 1, 2, satisfies the equation
uj(Qj) = Sj(t0 +Qj)− (1− q)Sj(t0) = 0, j = 1, 2. (3.1)
Or, equivalently,
Qj = S
−1
j ((1− q)Sj(t0))− t0, j = 1, 2,
where S−1j (.) is the inverse function of Sj(.). Thus as long as Sj(t) can be consistently
estimated, we can estimate Qj by plugging it into the right hand side of the above equation.
In Chapter 2 we have shown two methods (truncation product limit estimator and the
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length-bias corrected estimator) for consistently estimating the survival distribution from
length-biased censored survival data. We restate the two estimators here, except that they
are now indexed by j(j = 1, 2) to indicate respective populations.
The TPL estimator of Sj(.) from the length-biased data is calculated as
Sˆj(t) =
∏
u∈[0,t]
{1− dΛˆj(u)}, (3.2)
where
Λˆj(t) =
∫ t
0
dN¯j(u)
R¯j(u)
(3.3)
with N¯j(u) = n
−1
j
∑nj
k=1 ∆jkI(Yjk ≤ u) and R¯j(u) = n−1j
∑nj
k=1 I(Yjk ≥ u ≥ Ajk).
On the other hand, the survival estimator proposed by Huang and Qin (2011) is given
by
Sˆj
∗
(t) =
∏
u∈[0,t]
{1− dΛ˜j(u)} (3.4)
with
Λ˜j(t) =
∫ t
0
dN¯j(u)
R˜j(u)
, (3.5)
where
R˜j(u) = n
−1
j
nj∑
i=1
I(Yji ≥ u)− S˜jA(u),
S˜jA(u) =
∏
t∈[0,u]
{
1− dB˜j(t)
K˜j(t)
}
,
B˜j(t) = n
−1
j
nj∑
i=1
{I(Aji ≤ t) + ∆jiI(V˜ji ≤ t)},
and
K˜j(t) = n
−1
j
nj∑
i=1
{I(Aji ≥ t) + I(V˜ji ≥ t)}.
The above two estimators are then plugged into the Equation (3.1) and solved for Qj to
obtain an estimator of Qj. Thus the TPL estimator of Qj is the solution of the equation
uˆj(Qj) = 0,
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where
uˆj(Qj) = Sˆj(t0 + Qˆj)− (1− q)Sˆj(t0).
Or, equivalently,
Qˆj = Sˆj
−1
((1− q)Sˆj(t0))− t0
, where Sˆj
−1
(.) is the inverse of the estimated survival function defined in Chapter 2. Simi-
larly, we define the estimator Qˆj
∗
of Qj as the solution of the equation,
uˆ∗(Qj) = 0
for Qj where
uˆj
∗(Qj) = Sˆj
∗
(t0 +Qj)− (1− q)Sˆj∗(t0).
In other words,
Qˆj
∗
= Sˆ∗j
−1
((1− q)Sˆj∗(t0))− t0.
According to the results provided in Chapter 2, Qˆj and Qˆj
∗
are consistent and asymp-
totically normal for large nj, for j = 1, 2. Therefore, for testing H0 : Q1 = Q2 one may wish
to construct a usual Wald test such as
Qˆ1 − Qˆ2
SE(Qˆ1 − Qˆ2)
. (3.6)
Unfortunately estimating standard error of Qˆ1 − Qˆ2 is not straightforward as it involves
density estimates from censored survival data that are highly unstable (Padgett, 1984 [26]).
Here we propose to test the hypothesis based on the distribution of uˆj(Qj), which does not
require density estimates. Our derivation of the test statistic follows that of Su and Wei
(1993) and Jeong et al. (2008).
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3.2.3 Proposed Statistic
We recall from Chapter 2 that
√
njuˆj(Qj0) at the true value Qj0 is asymptotically distributed
as Normal with mean zero and variance
Vj(Qj0) = σ
2
j (t0 +Qj0) + (1− q)2σ2j (t0)− 2(1− q)Σj(t0 +Qj0, t0), j = 1, 2, (3.7)
where Σj(t1, t2) = E{φji (t1)φji (t2)}, 0 ≤ t1, t2 ≤ τ with σ2j (t) = Σj(t, t). The function φji (t)
is the influence function of the estimator Sˆj(t), and as shown in Chapter 2 is given by
φji (t) =
[∫ t
0
Rj(u)
−2I(Yji ≥ u ≥ Aji)dF uj (u)−
∆jiI(Yji ≤ t)
Rj(Yji)
]
Sj(t),
where F uj (t) = pr(∆j = 1, Yj ≤ t) is the sub distribution function of complete observations.
For known Qj0, this variance can be estimated by
Vˆj(Qj0) = Σˆ(t0 +Qj0, t0 +Qj0) + (1− q)2Σˆ(t0, t0)− 2(1− q)Σˆ(t0 +Qj0, t0),
where
Σˆ(t1, t2) =
1
nj
Σ
nj
i=1φˆ
j
i (t1)φˆ
j
i (t2)
with
φˆji (t) = Sˆj(t)
[∫ t
0
I(Yji ≥ u ≥ Aji)dN¯j(u)
R˜j
2
(u)
− ∆jiI(Yji ≤ t)
R˜j(Yi)
]
.
Similarly,
√
njuˆ
∗(Q)j0 is asymptotically distributed as Normal with mean zero and vari-
ance
V ∗j (Qj0) = σ
∗
j
2(t0 +Qj0) + (1− q)2σ∗j 2(t0)− 2(1− q)Σ∗j(t0 +Qj0, t0), j = 1, 2, (3.8)
where Σ∗j(t1, t2) = E{φji
∗
(t1)φ
j
i
∗
(t2)}, 0 ≤ t1, t2 ≤ τ with σ∗j 2(t) = Σ∗j(t, t). The function
φji
∗
(t) is the influence function of the estimator Sˆ∗j (t), and is given by
φji
∗
(t) = φji (t) +
∫ t
0
Rj(u)
−2{I(Aji > u)− SjA(u)− SjA(u)φji (u)}dF uj (u),
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i = 1, 2....., n, are i.i.d random variable with mean zero and the covariance function
Σ∗j(t1, t2) = E
[
φji
∗
(t1)φ
j
i
∗
(t2)
]
.
Vˆj
∗
(Qj0) = Σˆ
∗(t0 +Qj0, t0 +Qj0) + (1− q)2Σˆ∗(t0, t0)− 2(1− q)Σˆ∗(t0 +Qj0, t0),
Σˆ∗(t1, t2) =
1
nj
nj∑
i=1
φˆji
∗
(t1)φˆ∗i
∗
(t2),
with
φˆji
∗
(t) = Sˆ∗j (t)
[∫ t
0
I(Yji ≥ u ≥ Aji)dN¯j(u)
R˜j
2
(u)
− ∆jiI(Yji ≤ t)
R˜j(Yji)
+
∫ t
0
{
I(Aji > u
R˜j
2
(u)
− S˜jA(u)− S˜jA(u)ψ˜ji (u)
}
dN¯j(u)
]
,
where
ψ˜ji (u) =
∫ t
0
{I(Aji ≥ u) + I(V˜ji ≥ u)}dB˜j(u)
K˜j
2
(u)
− I(Aji ≤ t)
K˜j(Ai)
− ∆jiI(V˜ji ≤ t)
K˜j(V˜ji)
.
We consider the TPL test statistic
W (Q10, Q20) =
n1uˆ1
2(Q10)
Vˆ1(Q10)
+
n2uˆ2
2(Q20)
Vˆ2(Q20)
. (3.9)
Under H0 : γ = γ0 where, γ =
Q20
Q10
and γ0 is a known value,
W (Q20) =
n1uˆ1
2(γ0Q20)
Vˆ1(γ0Q20)
+
n2uˆ2
2(Q20)
Vˆ2(Q20)
, (3.10)
which depends on the true value Q20. If Q20 were known, this statistic would asymptot-
ically follow a χ2 distribution with two degrees of freedom as it is the sum of squares of two
independent standard Normal random variables. Since the true value Q20 is unknown, Su
and Wei (1993) suggested minimizing W (Q20) over the possible support of Q20. Following
their argument, under H0,
W = inf
Q20
W (Q20) (3.11)
follows a χ21 distribution as one degree of freedom has been lost due to the minimization of
Q20.
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Similarly, based on the Huang and Qin method, we define the statistic
W ∗ = inf
Q20
W ∗(Q20), (3.12)
where
W ∗(Q20) =
n1uˆ∗1
2
(Q20)(γ0Q20)
Vˆ1
∗
(Q20)(γ0Q20)
+
n2uˆ∗2
2
(Q20)
Vˆ2
∗
(Q20)
(3.13)
and W ∗(Q20) follows a χ21 distribution based on the same logic as before.
We investigate the properties of the two test statistics W and W ∗ in Equations (3.11)
and (3.12) via simulation in the next section.
3.3 SIMULATION STUDY
3.3.1 Data Generation
Data were generated from a Weibull distribution with scale and shape parameters (α1, β1)
and (α2, β2) for the two populations, where the values of α1, β1, α2, and β2 were varied to
investigate various shapes of the distributions. The Weibull distribution with parameters
(αj, βj), j = 1, 2 is given by the survival function
Sj(t) = exp
{
−
(
t
αj
)βj}
. (3.14)
For all the simulation scenarios described below, we first generated 1000 pairs of Monte-
Carlo samples of sizes n1 and n2. To generate n1 observations from the first population we
followed the following procedures. We set the sampling time (recruiting time) ξ to be 100.
The time of disease onset W 0 was generated from a Uniform distribution over the interval
[0, 100]. The survival time T 0 was independently generated from a Weibull distribution with
the survival function
S1(t) = exp
{
−
(
t
α1
)β1}
. (3.15)
To form a prevalent cohort of sample size n1, the pair (W
0, T 0) were generated repeatedly
until there were n1 pairs of observations satisfying the sampling constraint W
0+T 0 ≥ ξ. The
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residual censoring time C1 from enrollment to loss to follow-up was generated from a Uniform
distribution with a support (θ1, θ2), where θ1 and θ2 were varied to investigate varying
censoring rates. We followed the same procedure to generate n2 length-biased observations
from the second population with Weibull parameters (α2, β2) .
We conducted the test of equality of median residual life at time points 0.0, 0.5, and 1.0.
For each pair of Monte-Carlo samples, we calculated the test statistics W from Equation
(3.11) and W ∗ from Equation (3.12). If the statistic is larger than the critical value χ21,α (at
100α% level of significance), we reject the null hypothesis. For the 1000 sample pairs, we
count the number of sample pairs for which the null hypothesis is rejected. The proportion
of times the null hypothesis is rejected provides an estimate of the Type I error of the
test, if underlying populations satisfy the null hypothesis (median residual lifes for the two
populations are identical). On the other hand, it provides an estimate of power of the test
if the two population medians are not identical.
3.3.2 Simulation from the Null: Type I error
First we generated the data under the null hypothesis H0 : γ = 1, that is the two population
median residual life times are identical. To ensure this, in the first scenario we chose α1 =
α2 = 2, and β1 = β2 = 2 so that in the population median residual lifes for both populations
are the same. These medians are 1.67, 1.24, and .97 at 0.0, 0.5, and 1.0, respectively. Table
5 provides the estimated Type I errors for testing the equality of medians of the residual
life at time points 0.0, 0.5, and 1.0 for both truncation product limit (TPL) and Huang-Qin
(HQ) approaches. The censoring distribution parameters were taken to be θ1 = 1 and θ2 = 2
to give about 30% censored cases, and to be θ1 = 0 and θ2 = 2 to give about 51% censored
cases for both samples. We conducted the tests at α = 0.05 level of significance.
From the results in Table 5, we can see that empirical Type I errors are close to the
nominal level of 0.05, ranging between 0.033 and 0.064 for the TPL statistic W , and between
0.026 and 0.068 for W ∗. For earlier time points, both W and W ∗ are conservative in rejecting
the null hypothesis with empirical Type I errors being lower than the nominal level. This
may be due to the lack of variability in the survival estimates in the early time points.
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The tests maintain Type I errors well irrespective of censoring percentages and the sample
sizes, although sample sizes smaller than 100 tended to produce slightly unstable results (not
shown here) under the same levels of censoring. As can be seen, empirical Type I errors are
smaller for the test statistic W ∗ compared to W .
Table 5: Simulation results under the null hypothesis for testing H0 : γ = 1 versus H1 : γ 6= 1
under moderate and heavy censoring. Empirical Type I errors are based on 1000 Monte-
Carlo sample pairs of sizes n1 = n2 = n and α1 = 2 , α2 = 2, and β1 = 2, β2 = 2 in samples
1 and 2 respectively.
Censored t0 n W W
∗
0.0 0.045 0.035
0.5 200 0.047 0.052
1.0 0.063 0.067
30% 0.0 0.040 0.041
0.5 400 0.036 0.045
1.0 0.056 0.066
0.0 0.033 0.026
0.5 200 0.040 0.036
1.0 0.051 0.044
51% 0.0 0.037 0.035
0.5 400 0.044 0.046
1.0 0.064 0.068
We generated the data under other null distributions. For example, Table 6 provides the
results for α1 = α2 = 2.5, and β1 = β2 = 2 so that the population median residual life for
both populations are 2.08, 1.64, and 1.31 at 0.0, 0.5, and 1.0, respectively. The censoring
distribution parameters were taken to be θ1 = 1 and θ2 = 2 to give about 40% censored
cases, and to be θ1 = 0 and θ2 = 2 to give about 59% censored cases for both samples. We
conducted the tests at α = 0.05 level of significance. In this scenario, for the test statistic
W , estimated Type I error ranged between 2.7% to 5.4% under 40% censoring and between
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Table 6: Simulation results under the null hypothesis for testing H0 : γ = 1 versus H1 : γ 6= 1
under moderate and heavy censoring. Empirical Type I errors are based on 1000 Monte-
Carlo sample pairs of sizes n1 = n2 = n and α1 = 2.5 , α2 = 2.5, and β1 = 2, β2 = 2 in
samples 1 and 2 respectively.
Censored t0 n W W
∗
0.0 0.027 0.029
0.5 200 0.029 0.029
1.0 0.039 0.048
40% 0.0 0.038 0.035
0.5 400 0.035 0.044
1.0 0.054 0.069
0.0 0.034 0.033
0.5 200 0.035 0.039
1.0 0.039 0.052
59% 0.0 0.039 0.041
0.5 400 0.037 0.047
1.0 0.047 0.053
3.4% to 4.7% under 59% censoring. For the test statistic W ∗, estimated Type I error ranged
between 2.9% to 6.9% for moderate censoring and between 3.3% to 5.3% for heavy censoring.
An increase in sample size had no significant impact on the Type I error.
Table 7 provides the results for α1 = α2 = 3, and β1 = β2 = 2 so that the population
median residual life for both populations are 2.5, 2.0, and 1.7 at 0.0, 0.5, and 1.0, respectively.
The censoring distribution parameters were taken to be θ1 = 1 and θ2 = 2 to give about
48% censored cases, and to be θ1 = 0 and θ2 = 2 to give about 65% censored cases for both
samples. As before, the level of significance was set at α = 0.05. Note that the null survival
distribution here is more skewed to the right than the scenarios presented in Table 5 or in
Table 6, which is why censoring rates are higher than those two cases, even though we used
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Table 7: Simulation results under the null hypothesis for testing H0 : γ = 1 versus H1 : γ 6= 1
under moderate and heavy censoring. Empirical Type I errors are based on 1000 Monte-
Carlo sample pairs of sizes n1 = n2 = n and α1 = 3 , α2 = 3, and β1 = 2, β2 = 2 in samples
1 and 2 respectively.
Censored t0 n W W
∗
0.0 0.037 0.030
0.5 200 0.029 0.022
1.0 0.040 0.039
48% 0.0 0.041 0.036
0.5 400 0.038 0.039
1.0 0.056 0.055
0.0 0.029 0.027
0.5 200 0.028 0.026
1.0 0.042 0.040
65% 0.0 0.040 0.038
0.5 400 0.045 0.045
1.0 0.048 0.048
the same censoring distributions across the tables.
The results are very similar to the ones shown in Tables 5 and 6. Basically both tests are
conservative, with estimated Type I error being smaller than the nominal level of significance
for smaller sample sizes. For larger sample sizes, the empirical rejection rates are very close
to the nominal level, irrespective of the level of censoring. Generally tests of equality of
median residual life at time point 1 showed better performance in terms of matching the
nominal significance level.
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3.3.3 Power of the Test: Simulation under the Alternative
To investigate the power of the proposed tests under various conditions, we have generated
data from alternative hypotheses, varying the parameter values, censoring rates, and sample
sizes. The data are generated from the Weibull distribution as outlined above, except that to
investigate power we chose different parameter combinations for the two samples to ensure
that γ1 is not equal to 1.
Table 8: Simulation results under the alternative hypothesis for testing H0 : γ = 1 versus
H1 : γ = γ1 under moderate censoring. Empirical power (rejection rates) are based
on 1000 Monte-Carlo sample pairs of sizes n1 = n2 = n and α1 = 2.5 , α2 = 2, and
β1 = 2, β2 = 2. Approximately 40% and 30% observations are censored in samples 1 and 2
respectively.
n t0 Q1(0.5, t0) Q2(0.5, t0) γ1 W W
∗
200 0.0 2.1 1.7 1.25 0.552 0.621
0.5 1.6 1.2 1.32 0.618 0.689
1.0 1.3 0.9 1.39 0.803 0.845
400 0.0 2.1 1.7 1.25 0.837 0.899
0.5 1.6 1.2 1.32 0.895 0.940
1.0 1.3 0.9 1.39 0.975 0.991
In Table 8 we present the empirical power (proportion of Monte-Carlo sample pairs
for which the null hypothesis is rejected) for the first sample generated from the Weibull
distribution with parameters (α1 = 2.5, β1 = 2), and the second sample generated from the
Weibull (α2 = 2, β2 = 2). The true median residual life function at times (0.0, 0.5, 1.0) were
(2.1, 1.6, 1.3) for the first population and (1.7, 1.2, 0.9) for the second population, resulting
in the true ratio (1.25, 1.32, 1.39). For the results presented, the censoring distribution was
assumed to be Uniform with parameters (θ1 = 1, θ2 = 2) to give about 40% censored cases
in the first sample and 30% in the second sample.
The results show that the power of the test increases as the ratio of the two median
residual life (effect size) increases, which is expected by the theory of statistical power.
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For example, with sample size 200 for each sample, the empirical power of the W test is
(0.55, 0.62, 0.80) for the QRL ratios (1.25, 1.32, 1.39) at time points (0.0, 0.5, 1.0) respectively.
Corresponding empirical powers for W ∗ test are respectively (0.62, 0.69, 0.85). The empirical
power increases as the sample sizes are increased from 200 to 400. For this sample size under
the same censoring rates, the power ranged between 0.84 and 0.98 for W test and between
0.90 and 0.99 for W ∗ test.
Table 9: Simulation results under the alternative hypothesis for testing H0 : γ = 1 versus
H1 : γ = γ1 under heavy censoring. Empirical powers (rejection rates) are based on 1000
Monte-Carlo sample pairs of sizes n1 = n2 = n and α1 = 2.5 , α2 = 2, and β1 = 2, β2 = 2.
Approximately 59% and 51% observations are censored in samples 1 and 2 respectively.
n t0 Q1(0.5, t0) Q2(0.5, t0) γ1 W W
∗
200 0.0 2.1 1.7 1.25 0.413 0.483
0.5 1.6 1.2 1.32 0.448 0.522
1.0 1.3 0.9 1.39 0.656 0.723
400 0.0 2.1 1.7 1.25 0.715 0.809
0.5 1.6 1.2 1.32 0.775 0.849
1.0 1.3 0.9 1.39 0.909 0.954
Table 9 presents the empirical power for the tests for samples generated under the same
scenario as in Table 8 except that the censoring distribution was assumed to be uniform with
parameters (θ1 = 0, θ2 = 2) to have a heavier censoring rate of about 59% censored cases in
the first sample and 51% in the second sample. Naturally, because of higher censoring rates,
the power is smaller compared to that presented in Table 8. The results show a similar trend
as in Table 8 that the power of the test increases as the ratio of the median residual lifes
(effect size) increases and the empirical power increases as the sample sizes increase, except
that both tests have reduced power due to the higher censoring rates. In both scenarios,
the W ∗ test seems to consistently out-power the W test regardless of sample size, censoring
rates, or effect size.
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Table 10: Simulation results under the alternative hypothesis for testing H0 : γ = 1 versus
H1 : γ = γ1 under moderate censoring. Empirical power (rejection rates) is based on 1000
Monte-Carlo sample pairs of sizes n1 = n2 = n and α1 = 3 , α2 = 2, and β1 = 2, β2 = 2.
Approximately 48% and 30% observations are censored in samples 1 and 2 respectively.
n t0 Q1(0.5, t0) Q2(0.5, t0) γ1 W W
∗
200 0.0 2.5 1.7 1.50 0.949 0.966
0.5 2.0 1.2 1.65 0.974 0.985
1.0 1.7 0.9 1.80 0.999 1.000
400 0.0 2.5 1.7 1.50 >0.999 >0.999
0.5 2.0 1.2 1.65 >0.999 >0.999
1.0 1.7 0.9 1.80 >0.999 >0.999
Tables 10 and 11 shows the empirical power for first sample generated from the Weibull
distribution with parameters (α1 = 3.0, β1 = 2), and the second sample generated from the
Weibull (α2 = 2, β2 = 2). The true median residual life function at times (0.0, 0.5, 1.0) was
(2.5, 2.0, 1.7) for the first population and (1.7, 1.2, 0.9) for the second population, resulting in
the ratio (1.50, 1.65, 1.80). In Table 10, the censoring distribution was assumed to be Uniform
with parameters (θ1 = 1, θ2 = 2) to give about 48% censored cases in the first sample and 30%
in the second sample. On the other hand, Table 11 represents a heavier censoring scenario
where the censoring distribution was assumed to be Uniform with parameters (θ1 = 0, θ2 = 2)
to give about 65% censored cases in the first sample and 51% in the second sample.
These results show a similar trend as those seen in Tables 8 and 9 except that because of
the larger effect sizes, the empirical power is larger than that presented in those tables. The
power of the test increases as the ratio of the median residual lifes (effect size) or sample size
increases. Similar to the results shown before, the W ∗ test seems to consistently out-power
the W test regardless of the sample size, censoring rates, or effect size, but with larger sample
size of 400, under moderate censoring, the effect sizes of 1.5−1.8 resulted in almost identical
empirical power.
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Table 11: Simulation results under the alternative hypothesis for testing H0 : γ = 1 versus
H1 : γ = γ1 under heavy censoring. Empirical power (rejection rates) is based on 1000
Monte-Carlo sample pairs of sizes n1 and n2 and α1 = 3 , α2 = 2, and β1 = 2, β2 = 2 . C1
and C2 are percent censored in samples 1 and 2 respectively.
n t0 Q1(0.5, t0) Q2(0.5, t0) γ1 W W
∗
200 0.0 2.5 1.7 1.50 0.866 0.914
0.5 2.0 1.2 1.65 0.902 0.952
1.0 1.7 0.9 1.80 0.975 0.991
400 0.0 2.5 1.7 1.50 0.993 0.997
0.5 2.0 1.2 1.65 0.995 >.999
1.0 1.7 0.9 1.80 >0.999 >0.999
3.3.4 Impact of Sample Size and Alternative Ratio on Power
To investigate the impact of sample size on the power of the two tests, we have fixed the two
populations at Weibull (2.5, 2) and Weibull (2, 2) respectively with the alternative value γ1
being equal to 1.25, 1.32, and 1.40 at times 0.0, 0.5, and 1.0 respectively. Then keeping the
same censoring rates (40% in the first sample and 30% in the second) across all the sample
sizes ranging from 50 to 400, we computed the empirical power based on 1000 Monte-Carlo
pairs of samples. The resulting empirical power is plotted against the sample size in Figure 4.
This figure demonstrates that the power of both tests increases as the sample size increases,
and the power is relatively larger for the W ∗ test compared to the W test.
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Figure 4: Empirical power of tests as a function of sample size. Empirical power is calculated
by generating 1000 pairs of samples from Weibull (2.5, 2) and Weibull (2, 2) distributions
respectively. The censoring rates are respectively 40% for the first sample and 30% for the
second sample.
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To investigate the impact of the effect size on the power of the two tests, we have fixed the
sample size to 200 for each sample, however, the two populations were taken to be Weibull
(α1, β1) and Weibull (α2, β2) respectively, where (αj, βj), j = 1, 2 were chosen to obtain a
range of values of the “effect size” γ1 between 0 and 3. Then we computed the empirical
powers based on 1000 Monte-Carlo pairs of samples. The resulting empirical power is plotted
against the γ1 in Figure 5. At all the three time points considered, the power shows a similar
pattern across the valuses of γ1, with values close to the null (γ1 = 1) providing the lowest
power (approximately equal to 0.05, the level of significance), and the power increasing as
the γ1 deviated from 1 in either direction. Again, at any given value of γ1, the power is
relatively larger for the W ∗ test compared to the W test.
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Figure 5: Empirical power of tests as a function of effect size.
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3.4 DATA ANALYSIS
In this section we illustrate our method using the data from the National Surgical Adjuvant
Breast and Bowel Project (NSABP) protocol B-20 clinical trial. The study is described in
details in Chapter 2, where we used only one of the three arms (Tamoxifen only, TAM) to
demonstrate the application of our methods to estimate the quantile residual life function af-
ter recurrence for breast cancer patients being treated with tamoxifen. Here we additionally
included the Tamoxifen+ cyclophosphamide+sequential methotrexate+fluorouracil (follow-
ing Fisher et al. 1997[11]) (CMFT arm) and compare the median residual life following
recurrence across the two arms.
As described earlier, a total of 788 women were randomly assigned to receive Tamoxifen.
Out of these 788 women, 170 women experienced recurrence. To construct a length-biased
sample of patients, we identified the date of recurrence of the first patient who experienced
recurrence and set the recruitment time to be at 5 years following the first recurrence date.
By the recruitment date, 120 patients had died or lost-to-follow-up and hence would not be
eligible to be in the sample. Thus, our length-biased sample consists of 50 patients who had
recurrence prior to September 17, 1994 and were still being followed at the same date.
A total of 789 women were randomly assigned to receive CMFT. Out of these 789 women,
97 women experienced recurrence. Using the same recruitment date of September 17, 1994,
we obtained a length-biased sample of 26 patients who had recurrence and were still being
followed.
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Table 12 provides the estimates of median residual lifes for the two arms at recurrence,
half-year after recurrence, and one-year after recurrence using W as the test statistics. The
median residual lifetimes are generally larger, by approximately a half-year, in the Tamoxifen
arm compared to CMFT arm, however, the differences were not statistically significant.
Table 12: NSABP B-20 Data Analysis : Estimated median residual lifetimes along with 95%
confidence intervals (using Qˆ ) by treatment. The confidence interval for the ratio, and the
p-value for test is computed using W .
Qˆ(0.5, t0)
t0 TAM CMFT Ratios p− value
0.0 3.11 2.51 1.24 0.66
(1.49 - 10.3) (1.19-4.45) (0.42 - 1.72)
0.5 2.61 2.01 1.30 0.66
(0.99-9.82) (0.69-3.95) (0.3-2.08)
1.0 2.11 1.57 1.34 0.92
(0.49-9.32) (0.86-5.15) (0.44 - 5.0)
Table 13 provides the estimates of median residual lifes for the two arms at recurrence
using the other method. The point estimates of median residual life since recurrence differed
between the two methods (Table 12 vs. Table 13 ). However the estimate of the ratio of
median residual lifes using two methods was similar, as are the p-values, inferring that there
were no significant differences across the two arms in terms of median residual life since
recurrence, half-year or one year after recurrence.
In Figure 6, we plotted estimated median residual life function for breast cancer patients
with recurrence over time by treatment arm. Generally the median residual life is longer for
the tamoxifen group compared to the CMFT group at almost all time points.
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Table 13: NSABP B-20 Data Analysis : Estimated median residual lifetimes along with 95%
confidence intervals (using Qˆ∗ ) by treatment. The confidence interval for the ratio, and the
p-value for test is computed using W ∗.
Qˆ(0.5, t0)
t0 TAM CMFT Ratio p− value
0.0 2.36 2.04 1.16 0.56
(1.42 - 4.34) (1.06-3.66) (0.2 - 2.44)
0.5 1.86 1.54 1.21 0.56
(0.92-3.84) (0.56-3.16) (0.12 - 3.18)
1.0 1.36 1.09 1.24 0.96
(0.42-3.34) (0.19-3.29) (0.14 - 5.0)
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Figure 6: Estimated median residual life function plotted over time for NSABP B-20 data
by treatment arm.
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3.5 DISCUSSION
In the presence of length-biased data which are left truncated, regular Kaplan-Meier curves
are not applicable (Klein and Moeschberger, chapter 4, section 6, [24]) and hence a test
based on the Kaplan-Meier curve can be misleading. In this chapter we have proposed two
test statistics for testing the equality of quantiles of residual life functions for length-biased
right-censored survival data. One test statistic W is based on the truncation product-
limit estimator of survival distribution, and the other statistic W ∗ based on an estimator of
the survival distribution (Huang and Qin, 2011) that takes into account the fact that the
marginal distribution of the truncation time is the same as that of the residual survival time
(time since recruitment to terminating event). The two tests both follow an asymptotic χ21
distribution. Our simulation studies demonstrated that for reasonable sample sizes, both
tests maintain Type I error under various censoring proportions ranging as high as 65%.
When sample sizes are small, e.g., n <= 100 per group, the test statistics do not perform
well with Type I error being much smaller than the nominal level. Moreover, when the
sample sizes are unequal, both tests require larger sample sizes per group than when the
sample sizes are equal. Generally, the power for the W ∗ test is larger than that for the W
test.
Length-biased data assume that the initial event occurs at a stable rate, which means
that the truncation time given the overall survival is uniformly distributed. A consequence of
this result is that the marginal distribution of the truncation time (A) is the same as that of
the residual survival time (V ). Asgharian et al. (2006) suggested checking this stationarity
assumption by comparing the estimated survival distribution of A and V graphically. We
presented the survival curves for A and V for the NSABP B-20 data in Figure 7. These
estimates are obtained using regular Kaplan-Meier method. Unfortunately the two survival
curves are not similar for this data set. This may be due to the fact that the recurrence
(initial event) rates may not be stable over time in this population and hence it is likely that
the stationarity assumption is violated.
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Figure 7: Graphical check for stationarity assumption. The red curve is the survival distri-
bution of the forward survival (time since recruitment) to the terminating event or censoring;
the black curve is the survival distribution of the truncation time or backward survival time.
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4.0 CONCLUSION AND DISCUSSION
In a study of the natural history of a disease ( e.g., cancer), it is often of interest to estimate
the survival from the onset of a non-terminal initial event (e.g. recurrence) to a terminal
event (death). For example, in a study of hepatitis B, it may be of interest to estimate the
survival distribution of a population of patients who acquired hepatitis B; or among patients
with hepatitis B, the interest may be to estimate the median time between the occurrence of
hepatocellular carcinoma (HCC) and death. To estimate such quantities, one needs to draw
a sample of individuals from the respective population. One possible way to obtain such a
sample is to start with a random sample of individuals without the initial event (disease,
recurrence, HCC) from the population and then follow them to the occurrence of the initial
event. Individuals with the initial event are then followed until the occurrence of the terminal
event. This process is known as incidence sampling. Incidence sampling renders several
practical inconveniences for a researcher as it might take a very large sample to start with
to ensure a reasonable number of individuals experience the initial event. Subsequently, it
might take a long follow-up to ensure a reasonable number of these individuals to experience
the terminal event in order to draw valid conclusions.
An alternative sampling scheme is prevalence sampling, where individuals who have
already experienced the initial event but not the terminal event are recruited into the sample
at a specific time and are followed until the terminal event. Prevalence sampling reduces
the need for a large starting cohort, and possibility, the long follow-up time required in
incidence sampling. However, prevalent sample is generally biased. The bias arises due to
the fact that people who experienced the terminal event earlier than the recruitment date
would not be included in the sample. In other words, individuals with shorter survival times
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(time between initial and terminal event) would not be recruited into the sample, and hence
the survival based on prevalence sample will generally be overestimated. This bias is called
length bias. One important characteristic of length-biased data is that the initial event
occurs at a constant rate, which usually is violated if there is an epidemic or if there is an
improvement in the diagnosis of the disease.
Survival data from prevalence sampling is naturally left-truncated. Since the follow-
up time is often limited, and drop-out may occur at any time during follow-up, the data
may also be right-censored. In the last several decades, many authors have addressed the
issues of left-truncation and right censoring in survival analysis (Wang et al., 1986[37]; Tsai
et al., 1987[29]; and references therein). There is a version of the product-limit estimator
(called the truncation product limit estimator [[22], [37]]) that provide an unbiased estimate
of the survival function in the presence of left-truncation and independent right-censoring.
However, this estimator does not take into account the uniform distribution of the left
truncation times (or stationarity), and hence is inefficient. If the incidence rate remains
constant over time (Wang, 1991)[35], i.e., if the stationarity assumption holds, the truncation
time will follow a Uniform distribution and an estimator that incorporates the truncation
time distribution is generally more efficient (Vardi, 1982[31], 1985[32], 1989[32], Gill et al.,
1988[15], Vardi and Zhang (1992)[33], Asgharian et al., 2002[2], and Asgharian and Wolfson,
2005[3]) than truncation product limit estimator. Vardi ’s (1982[31], 1985[32]) nonparametric
maximum likelihood estimator (NPMLE) is not easy to implement while Huang and Qin ’s
(Huang and Qin, 2011[17]) new non-parametric estimator has a closed-form expression and
is almost as efficient as the NPMLE.
In this dissertation, we provided methods for inference about quantile residual life func-
tion from right-censored length-biased data based on prevalence sampling. We used TPL and
Huang and Qin survival curves to derive estimators of the quantiles of residual life distribu-
tion. Since it is not easy to obtain a stable variance estimator, we used a Brookmeyer-type
approach (1982, [6]) to construct point-wise confidence intervals for quantiles of residual
life. Simulation under various conditions indicated that the proposed confidence intervals
maintain nominal coverage and the Huang and Qin approach provides narrower confidence
intervals. We also proposed two tests based on the two approaches of estimation. Both tests
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maintain Type I error. However, the Huang and Qin approach is generally more power-
ful than the TPL approach. We demonstrated our methods by estimating the quantiles of
residual life functions following recurrence in breast cancer patients.
In this dissertation we used non-parametric methods to estimate the survival curves
and draw inference about the quantiles of the residual life. Future research might assume
parametric models for the survival distributions and then can use likelihood-based approaches
to derive estimators and statistical tests. It would be interesting to see how such estimators
or tests compare to the proposed non-parametric counterparts. One other extension would be
to formulate regression-based approaches to adjust for covariates while comparing quantiles
of residual life across groups.
There is important public health significance to the proposed work. As mentioned earlier,
public health professional (PHPs) and clinicians are often interested in studying the time
between the occurrence of an initial event and a terminating event, e.g., the time between
recurrence and death, the time between the onset of depression and the remission. This helps
PHPs develop policies for better treatment of individuals. For example, after recurrence of
breast cancer, a women can make a better informed decision about treatment choices if
she knows what her median residual life would be under different treatment options. Our
methods provide accurate and efficient estimators of the median and quantiles in general of
the residual life at a specific time point and hence can serve the purpose.
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